Skip to main content
ABIVAX logo

ABIVAX — Investor Relations & Filings

Ticker · ABVX ISIN · FR0012333284 LEI · 969500D8TMNB184OJU95 PA Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2020-01-20 Report Publication Anno…
Country FR France
Listing PA ABVX

About ABIVAX

https://www.abivax.com

Abivax is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases by regulating the immune system. The company's scientific approach is centered on harnessing microRNA (miRNA) biology. Its lead drug candidate, obefazimod, is an investigational, once-daily, oral small molecule with a novel mechanism of action that enhances the expression of miR-124, a natural regulator of the inflammatory response. The primary development program for obefazimod focuses on ulcerative colitis, for which the company has reported positive Phase 3 clinical trial results. Abivax is also investigating the candidate for the treatment of Crohn's disease and other inflammatory conditions, while exploring follow-on compounds.

Recent filings

Filing Released Lang Actions
ABIVAX: Finanzkalender 2020
Report Publication Announcement Classification · 1% confidence The document is titled "ABIVAX: Finanzkalender 2020" (Financial Calendar 2020) and explicitly lists future dates for key corporate events, such as the release of the 2019 Annual Financial Statements, the Annual General Meeting (Hauptversammlung), and the release of the 2020 Half-Year Report. This type of announcement, which schedules future reporting dates, is a general corporate communication. Since it is not the report itself (like 10-K or IR), and it doesn't fit specific categories like Dividend (DIV), Director's Dealing (DIRS), or Management Changes (MANG), it falls best under the general regulatory announcement category, 'Regulatory Filings' (RNS), as it is a formal notification to the market about future corporate actions/reporting schedules, distributed via DGAP-News.
2020-01-20 German
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is titled "2020 Financial Communication Calendar" and explicitly states that ABIVAX SA is "publishing its 2020 financial communication calendar." It lists future dates for the publication of various reports (2019 Financial Statements, 2019 Annual Financial Report, 2020 Half Year Report) and a Shareholders meeting. Since the document itself is an announcement detailing *when* other reports will be released, rather than being one of the reports (like 10-K, IR, or ER), it fits the definition of a Report Publication Announcement (RPA). The document length (3829 chars) is short enough to support this classification based on the 'MENU VS MEAL' rule.
2020-01-20 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "Calendrier de communication financière 2020" (2020 Financial Communication Calendar) and lists future dates for key corporate events, specifically mentioning the publication of annual results, the annual general meeting (Assemblée Générale annuelle), and the publication of the semi-annual report. Since the document itself is an announcement detailing *when* other reports will be released, rather than being one of the reports (like 10-K, IR, or ER), it fits the definition of a Report Publication Announcement (RPA). The document length (3955 chars) is short, supporting the idea that it is an announcement rather than a full report.
2020-01-20 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states it provides 'Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du code de commerce et l'article 223-16 du règlement général de l'Autorité des Marchés Financiers.' It presents a table detailing the 'Nombre d'actions' and 'Nombre total de droits de vote' as of a specific date (30/11/2019). This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing requirement in France, often related to changes in major shareholdings or capital structure transparency. While it touches upon share capital, the core content is the official count of voting rights. This fits best under Major Shareholding Notification (MRQ) or potentially a general Regulatory Filing (RNS). Given the specific focus on voting rights and share count disclosure mandated by AMF regulations, MRQ is the most precise fit, as these reports are often triggered by crossing shareholding thresholds, even if this specific document is just the periodic update.
2019-12-20 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated November 21st, 2019, announcing regulatory approval (ANSM) for a clinical trial (Phase 2b Ulcerative Colitis) and providing progress updates on other clinical development plans (Rheumatoid Arthritis, Crohn's disease). It details trial specifics, interim results, and future expectations. This content structure—a formal announcement of operational and clinical progress, often released outside of mandatory quarterly/annual filings—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses on clinical trial progress and regulatory milestones rather than comprehensive financial results (which would suggest ER or IR), and it is a formal announcement, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release if it were tied to a specific reporting period's results announcement. Given the focus on clinical updates and regulatory milestones rather than just financial highlights, RNS is a strong candidate. However, press releases detailing operational updates and clinical progress are frequently categorized as Earnings Releases (ER) when they serve as the primary communication vehicle for company performance updates outside of the formal 10-K/IR cycle. Since it provides a 'Progress Update' and discusses trial results (which often accompany earnings), ER is a very strong fit, as it's a scheduled communication about company performance. Given the context of a biotech company, clinical updates are core performance indicators. I will classify it as an Earnings Release (ER) because it functions as a performance update announcement, even if the performance metrics are clinical rather than purely financial, which is common for biotech press releases. Revisiting the definitions: ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document is more about clinical/regulatory milestones than financial highlights. LTR (Legal Proceedings Report) is incorrect. CT (Call Transcript) is incorrect. IP (Investor Presentation) is incorrect. Given the nature of the announcement (regulatory approval, trial progress, CEO commentary), it is a general corporate update. RNS (Regulatory Filings) is the best fallback for non-specific corporate announcements. Since it is not a full report (like 10-K or IR) but an announcement, and it doesn't fit perfectly into ER (which implies financial results), RNS is the most appropriate general category for this type of press release.
2019-11-21 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated November 21, 2019, announcing that ABIVAX has received authorization from the French regulatory authorities (ANSM) to include French sites in its Phase 2b clinical trial for ABX464 in ulcerative colitis. It also provides updates on other ongoing and planned clinical trials (Rheumatoid Arthritis, Crohn's disease) and discusses the mechanism of action and preliminary results from Phase 2a studies. This content—an update on clinical trial progress, regulatory milestones, and scientific data presentation—is characteristic of an announcement intended for investors and the public regarding ongoing operations and pipeline development, rather than a formal periodic financial report (like 10-K or IR) or a transcript. Since it is a general announcement about company progress and clinical development, it fits best under the 'Regulatory Filings' (RNS) category as a general corporate update, although it contains elements of an Investor Presentation (IP) summary. Given the format (press release announcing regulatory/clinical progress) and the lack of a specific category for 'Clinical Trial Updates', RNS serves as the most appropriate general regulatory announcement fallback, though 'IP' is a close second if the focus is purely on investor communication. However, since it is a formal press release detailing regulatory clearance and trial status, RNS (Regulatory Filings) is the standard classification for such non-standardized corporate news releases.
2019-11-21 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.